The emerging role of endothelin-1 in the pathogenesis of subchondral bone disturbance and osteoarthritis  by Sin, A. et al.
Osteoarthritis and Cartilage 23 (2015) 516e524ReviewThe emerging role of endothelin-1 in the pathogenesis of subchondral
bone disturbance and osteoarthritis
A. Sin y ¶ a, W. Tang y a, C.Y. Wen y * a, S.K. Chung z x k, K.Y. Chiu y
y Department of Orthopaedics and Traumatology, The University of Hong Kong, Pokfulam, Hong Kong
z Department of Anatomy, The University of Hong Kong, Pokfulam, Hong Kong
x Heart, Brain, Hormone and Healthy Aging Center, The University of Hong Kong, Pokfulam, Hong Kong
k State Key Laboratory for Pharmaceutical Biotechnology, LKS Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong
¶ Georgetown University Medical Center, Washington, DC 20057, USAa r t i c l e i n f o
Article history:
Received 11 April 2014
Accepted 2 November 2014
Keywords:
Osteoarthritis
Endothelin-1
Subchondral bone* Address correspondence and reprint requests to
thopaedics & Traumatology, The University of Hong
Block, LKS Faculty of Medicine, Sassoon Road 21#, P
Tel: 852-39176987; Fax: 852-28185210.
E-mail address: paulwen@hku.hk (C.Y. Wen).
a Authors equally contribute to this work.
http://dx.doi.org/10.1016/j.joca.2014.11.002
1063-4584/© 2014 Osteoarthritis Research Society Ins u m m a r y
Mounting evidence suggests reconceptualizing osteoarthritis (OA) as an inﬂammatory disorder. Trauma
and obesity, the common risk factors of OA, could trigger the local or systemic inﬂammatory cytokines
cascade. Inﬂammatory bone loss has been well documented; yet it remains largely unknown about the
link between the inﬂammation and hypertrophic changes of subchondral bone seen in OA, such as
osteophytosis and sclerosis. Amid a cohort of inﬂammatory cytokines, endothelin-1 (ET-1) could stim-
ulate the osteoblast-mediated bone formation in both physiological (postnatal growth of trabecular
bone) and pathological conditions (bone metastasis of prostate or breast cancer). Also, ET-1 is known as a
mitogen and contributes to ﬁbrosis in various organs, e.g., skin, liver, lung, kidney heart and etc., as a
result of inﬂammatory or metabolic disorders. Subchondral bone sclerosis shared the similarity with
ﬁbrosis in terms of the overproduction of collagen type I. We postulated that ET-1 might have a hand in
the subchondral bone sclerosis of OA. Meanwhile, ET-1 was also able to stimulate the production of
matrix metalloproteinase (MMP)-1 and 13 by articular chondrocytes and synoviocytes, by which it might
trigger the enzymatic degradation of articular cartilage. Taken together, ET-1 signaling may play a role in
destruction of bone-cartilage unit in the pathogenesis of OA; it warrants further investigations to
potentiate ET-1 as a novel diagnostic biomarker and therapeutic target for rescue of OA.
© 2014 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Osteoarthritis (OA) is the most common of age-related degen-
erative joint disorders. It is a leading cause of pain and disability
among older adults. OA is a whole joint disorder with low-grade
inﬂammation, afﬂicting articular cartilage, subchondral bone,
synovium, ligaments and joint capsule. The hallmark of OA is the
degradation of articular cartilage. The integrity of articular cartilage
relies on the interplay with the other joint tissues, in particular
subchondral bone1. On the basis of hypertrophic changes of sub-
chondral bone such as osteophytosis and sclerosis, OA is differen-
tiated from the other types of arthritis, e.g., rheumatoid arthritis
(RA).: C. Wen, Department of Or-
Kong, L912, 9/F, Laboratory
okfulam, HKSAR, Hong Kong.
ternational. Published by Elsevier LRecently, mounting evidence suggests that OA should be
conceived as an inﬂammatory disease rather a simple wear-and-
tear problem2. The complements system was found to play a cen-
tral role in the initiation and deterioration of cartilage damages2.
Joint trauma and incurred joint instability could activate local in-
ﬂammatory response. Transforming growth factor-b1 (TGF-b1), a
key inﬂammatory mediator, was activated at subchondral bone in
response to anterior cruciate ligament transection (ACLT) to initiate
the onset of OA in a mice model3. Obesity is a recognized risk factor
of OA4. As part of metabolic syndrome (MetS), diabetes was also
proposed as an emerging independent risk factor of OA5. We once
observed a signiﬁcant bone loss at subchondral plate in OA patients
with the comorbidities, i.e., hypertension and diabetes6. Systemic
inﬂammation is a hallmark of MetS. Inﬂammatory bone loss has
been documented in RA7, yet the biological link between inﬂam-
mation and the disturbances at OA subchondral bone, in particular
its hypertrophic or sclerotic changes, remains largely unknown.
Actually, osteoblasts derived from sclerotic bone of OA patients
exhibited high proﬁle of inﬂammatory cytokines including TGF-b1,td. All rights reserved.
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and etc.8. Amid a cohort of inﬂammatory cytokine mediators,
endothelin-1 (ET-1) is known to mediate physiological and patho-
logic bone formation9. In addition, ET-1 has been implicated in the
degradation of articular cartilage in either inﬂammatory or
degenerative arthritis10e15. Meanwhile, high level of plasma ET-1
was also identiﬁed in the obese individuals and patients with hy-
pertension and diabetes16. All data pointed in the direction that ET-
1 could be one of candidate inﬂammatory factors to govern the
hypertrophic changes of subchondral bone, as a sequel of local and
systemic inﬂammation, in the pathogenesis of OA. We therefore
aimed to identify the information gap regarding the role of ET-1 in
OA subchondral bone disturbance by the integration and inter-
pretation of the existing data about ET-1 signaling in inﬂammation,
arthritis, the physiological and pathologic bone formation and etc. It
would provide a new insight intomolecular mechanism underlying
the destruction of boneecartilage unit and shed light on the dis-
covery of therapeutic targets for OA.
ET-1, inﬂammation and ﬁbrosis
ET-1, a 21-amino acid peptide, was ﬁrst discovered as a potent
vasoconstrictor in 198817. It has two structurally similar G protein-
coupled receptors, endothelin type A receptor (ETAR) and type B
receptor (ETBR). It is received that ETAR is responsible for trans-
ducing the most of biological effects of ET-1 while ETBR serves
primarily as a clearance receptor18. ET-1 is synthesized as preproET-
1 that is cleaved to form the precursor big ET-1 or proET-1. Endo-
thelin converting enzyme-1 converts big ET-1 to form the active
peptide ET-119. Big ET-1 only has 1/100 of the potency of mature ET-
1. Extracellular conversion to ET-1 could elicit sufﬁcient stimulus
for biological processes subsequently18.
ET-1 and nitric oxide (NO) act against each other to maintain
vascular homeostasis and the balance of vasoconstriction and
vasodilation20. Hypertension could be a result of the disturbed
balance between ET-1 and NO21. The overexpression of ET-1 spe-
ciﬁcally in endothelial cells using tie-1 promoter could lead to
systemic hypertension with altered vascular reactivity in a mouse
model22. A reduction of systemic blood pressure in patients with
essential hypertension by ET-A receptor antagonists further
demonstrated the link between ET-1 signaling and hypertension23.
Moreover, insulin has been shown to induce ET-1 production at the
transcriptional level24, and ET-1 may involve in the vicious cycle of
insulin resistance in the pathogenesis of diabetes25.
Also, ET-1 may contribute to the complications of hypertension
or diabetes such as the ﬁbrosis of heart, lung, kidney and skin by
activating the inﬂammatory and ﬁbrotic signaling pathways26,27.
The severity of ﬁbrosis appeared in an association with the level of
local ET-128. Growing bodies of evidence suggested that ET-1
cooperated with TGF-b1, a known pro-ﬁbrotic factor, in theTable I
Endothelin signaling in various types of arthritis and other musculoskeletal disorders
Authors Type of arthritis Specimen
Nahir AM et al.12 RA, OA Synovial ﬂuid
Haq A et al.10 RA Serum and synovial ﬂuid
Yoshida H et al.11 RA Synovial cells
Iwabuchi H et al.36 RA, OA Synovial ﬁbroblasts
Miyasaka N et al.87 Inﬂammatory arthritis Synovial ﬂuid
Roy-Beaudry M et al.15 OA Articular chondrocyte
Manacu CA et al.14 OA Articular chondrocyte
Wei Yuan et al.45 Lumbar disc degeneration Cells from endplate
Abbreviation: ET-1, endothelin 1; RA, rheumatoid arthritis; OA, osteoarthritis; TNF-a, tu
metalloproteinase 1/13; TIMP-1, tissue inhibitor of metalloproteinase-1.pathogenesis of ﬁbrosis in various tissues29e31. Blockade of endo-
thelin signaling either pharmaceutically (ETAR or ETBR antagonists
or neutralizing antibodies) or genetically (ETAR or ETBR siRNA)
could decrease the secretion of TGF-b by ﬁbroblasts and attenuate
the ﬁbrosis phenotype26. TGF-b1 also promoted ET-1 production in
a Smad2/3-dependent fashion in skin ﬁbroblasts29. In the ﬁbrotic
lung ﬁbroblasts, TGF-b1 activates ET signaling through type I re-
ceptor and then downstream ALK5/c-Jun N-terminal kinase (JNK)/
Ap-1 signaling that is independent of Smad proteins30. The dual
ETA/ETB receptor antagonist, e.g., Bosentan, could interrupt the
constitutive JNK activation in ﬁbrotic ﬁbrolasts, providing the evi-
dence of an autocrine endothelin loop of ET-1 in its ﬁbrotic effects.
In addition, ET-1 may exert its ﬁbrotic effects by activating a tissue
factor/thrombin ampliﬁcation loop, which is responsible for the
production of connective tissue growth factor (CTGF)31. Last but not
least, the endothelial mesenchymal transition (EndMT) process was
also implicated in the ET-1-mediated ﬁbrosis32. Taken together,
targeting the axis of TGF-b1/ET-1 signaling is likely to be of beneﬁt
in battling with ﬁbrotic disorders.
ET-1 and arthritis
ET-1 has been implicated as a major informatory mediator in
various autoimmune diseases such as RA33 and scleroderma34
(Table I). It was reported that both local (synovial ﬂuid) and sys-
temic (serum) levels of ET-1 were signiﬁcantly higher in RA pa-
tients than in healthy subjects10. Synovial macrophage-like cells
could produce ET-135 that interacted with the other inﬂammatory
cytokines such as tumor necrosis factor-a (TNF-a) and IL-1b to
regulate the adhesion proteins production, e.g., intercellular
adhesionmolecule-1, vascular cell adhesionmolecule-1, CD106 and
CD44 in cultured synovial ﬁbroblasts36,37. It supports a notion that
ET-1 plays a role in the inﬂammatory responses of synovitis by
recruiting neutrophil and endothelial cells to inﬁltrate the inﬂamed
tissue in arthritis38. Moreover, the elevated level of local ET-1 was
also linked up to the extra-articular manifestations of RA, e.g., hy-
pertension39. IL-6, the most abundant pro-inﬂammatory cytokines
in the serum and synovial joints of RA, could directly induce the
preproET-1 mRNA expression in the ﬁbrotic kidney with angio-
tensin II-induced hypertension27.
ET-1 could exert its direct effects on articular chondrocytes as
well as the synovial inﬂammation and ﬁbrosis. Articular chon-
drocytes themselves rarely express ET-1 unless the natural aging
process13 or diseased conditions14,15. In addition, the expression
level of ET receptors on articular chondrocytes was also affected by
the age as well as various growth factors and cytokines including
platelet derived growth factor-BB (PDGF-BB), TGF-a, TNF-a, IL-1b
and etc.40,41. The ET-1- binding sites on articular chondrocytes were
predominantly of ETAR41. The number of ET-1 binding sites on the
aged chondrocytes was approximately twice as many as theFindings
Endothelin level in synovial ﬂuid of RA was similar to in OA.
ET-1 level in serum and synovial ﬂuid of RA patients was higher than normal.
Synovial macrophage-like type A cells could produce ET-1.
TNF-a up-regulated ICAM-1 in RA and OA ﬁbroblasts while ET-1 inhibited this
process.
ET-1 in synovial ﬂuid was higher than serum.
ET-1 induced MMP-1 and 13.
ET-1 caused NO, MMP1 and MMP13 overexpression.
ET-1 increased MMP-1 and MMP-13, decreased TIMP-1, and induced NO.
mor necrosis factor-alpha; ICAM-1, Intercellular Adhesion Molecule 1; MMP-1/13,
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chondrocytes to ET-1 stimuli in vitro could be enhanced in the
presence of PDGF-BB, TNF-a, and IL-1b, but diminished with TNF-
a40,41. It strongly suggested that ET-1 was involved in regulating the
cellular metabolism in health, and presumably in the aged and
disease chondrocytes. Local level of ET-1 in OA joint was compa-
rable to RA12. The elevated ET-1 could provoke the expression of
matrix metalloproteinase (MMP)-1 and MMP-13 by osteoarthritic
chondrocytes in vitro15,16, the major enzyme to decay the cartilag-
inous matrix in the process of OA14,15. We further observed that
overexpressing endothelial ET-1 exaggerated hypertrophic differ-
entiation of articular chondrocytes with thickening calciﬁed carti-
lage that caused the structural damage to hyaline cartilage in a
transgenic mouse model42. On the other side, ET-1 could stimulate
the proteoglycan and collagen production by articular chondrocyte
in a dose- and time-dependent manner43,44. The stimulatory effect
of ET-1 in the ﬁrst 24-h were gradually decreased and ﬁnally
inhibited with prolonged incubation. NO mediated such inhibition
of ET-1 effects. Very recently, local level of ET-1 was also linked up
to the dysfunctional disc cells in the degeneration of lumbar
intervertebral disc45.
ET-1 may have a hand in mediating the inﬂammation-induced
pain, a major complaint from arthritis patients. It was found that
the subcutaneous injection of ET-1 could produce pain behavior
and activate the nociceptive C-ﬁbers in a doseedependent
manner46. Use of ETAR antagonist or knockout of ETBR signiﬁcantly
reduced both the subcutaneous and joint pain in rats46,47. It has
been documented that ETAR antagonists, in conjunction with bra-
dykinin receptor antagonists, were able to lessen the pain and
protect themorphology of OA knee joint in an ACLTmousemodel48.
However, not all of patients with the radiologic OA are symptom-
atic, in the other words, present the painful joints. The poor cor-
relations of the common ﬁndings from x-radiographwith pain pose
a big challenge in the management of OA49. The mechanical or
inﬂammatory stimuli activated the expression of nerve growth
factor (NGF) by articular chondrocytes and stimulated nerve in-
growth at the osteochondral junction, which may involve in the
arthritic joint pain50,51. It has been known that ET-1 could control
the NGF production in cardiac innervation52. Thus, we postulated
that ET-1 might play a role in mediating pain and nerve in-growth
at the osteochondral junction in OA. If so, ET-1 would be a prom-
ising biomarker for OA pain.
By contrast, the exact role of ET-1 in the disturbance of sub-
chondral bone in arthritic joint remains largely unknown. Unlike
the common x-radiographic ﬁndings, the edema-like changes un-
der magnetic resonance imaging, i.e., so-called bone marrow le-
sions (BMLs), were found in an associationwith the severity of pain
in OA49. BMLs were characterized histologically by the sclerotic
bone but less mineralized53. Osteoblasts derived from the sclerotic
bone of OA overproduced collagen type I with the aberrant
composition of alpha1 and alpha2 chains, and subsequently led to
poor mineralization54. High level of inﬂammatory cytokines or
mediators including TGF-b1, IL-1b, IL-6 and PGE2 may constitute
the defective osteoblasts8. The defective osteoblasts could alter the
phenotype of normal articular chondrocytes towards hypertrophic
differentiation by suppressing the expression of parathyroid hor-
mone related protein (PTHrP) and increasing the level of MMP-
1355. Neutralizing the activities of such inﬂammatory cytokines or
mediators such as TGF-b1 could restore aberrant overproduction of
collagen type I by defective osteoblasts in vitro54, and attenuate the
severity of OA in vivo3. Given the similarity between the ﬁbrotic and
sclerotic processes in terms of type I collagen overproduction, we
postulated that the axis of TGF-b1/ET-1 signaling, the known key
regulators in ﬁbrosis, may play a role in the sclerotic changes of OA
subchondral bone.ET-1 in physiological and pathological bone formation
Role of ET-1 in the maintenance of bone homeostasis and
regulation of osteoblastic function has been widely discussed
(Table II). It was found that mice deﬁcient in ET-1 had the cranio-
facial abnormalities of poorly developedmandibles and lower bone
mass56,57. It suggested that ET-1 was involved in intramembranous
ossiﬁcation process of ﬂat bone. When ETAR was speciﬁcally inac-
tivated in the osteocalcin-positive osteoblasts, trabecular bone
mass and volume in long bone, i.e., tibia, were signiﬁcantly
decreased in mice9. It indicated the regulatory role of ET-1 in the
postnatal development of long bone, possibly involving an endo-
chondral ossiﬁcation process. Moreover, the male and female mice
showed different responses to the knockout of ETAR. Such gender
difference did imply the interactions of sex hormone, particularly
androgen, with ET-1 signaling in mediating bone metabolism. It
warrants the further investigations to look for the direct evidence
from the castration and ovariectomy models.
In agreement with the in vivo data, the most of in vitro studies
demonstrated that the exogenous ET-1 promoted the differentia-
tion and proliferation of osteoblast precursors58e60. The effects of
ET-1 stimuli transduced through an integral membrane protein,
connexin-43 for osteoblast differentiation60. Then it could increase
the mRNA synthesis of osteopontin and osteocalcin, the markers of
mature osteoblasts, and stimulate the production of alkaline
phosphatase (ALP) and type I collagen61. As a potent regulator of
bone metabolism, the exogenous ET-1 might also interfere with the
mineralization process of osteoblasts62e64. But the results gener-
ated from the previous studies remain questionable as the MC3T3-
E1 cell lines and the transformed osteoblasts in osteosarcoma being
tested tended to be over-mineralized and they might not be a good
model to investigate the physiologic bone mineralization process.
Compared to osteoblasts, the information about ET-1 function in
osteoclasts is limited and ambiguous. ET-1 was detected in the
membrane and cytoplasm of osteoclasts by immunostaining65. It
implies that osteoclasts might be one of the target cells for ET-1
stimuli. By adding ET-1 (2e8 nM) to osteoclasts culture, the
osteoclasts-mediated bone resorption was decreased and the cell
motility was also inhibited66. The opposite results were reported in
another study on orthodontic tooth movement. It was found that
ET-1 could increase osteoclastic bone resorption via ETAR67,68. ET-1
was the predominant form of endothelins isoforms in the late stage
of orthodontic tooth movement69. The nanomolar level of ET-1 was
able to stimulate osteoclastic activity. Endothelial cells and their
producing ET-1 in bone may regulate bone remodeling by con-
trolling osteoclastic activities and bone resorption.
ET-1 signaling also contributed to the pathological bone for-
mation, e.g., osteoblastic metastasis in prostate cancer70. High level
of ET-1 produced by the prostate cancer cell lines (DU-145 and
LNCaP) could stimulate BMP-induced bone growth in vitro70, and
bone metastasis via interacting with ETAR58,71. The ET-1 signaling
antagonists have been proposed to control the progression of bone
metastasis in prostate cancer72.
The extracellular molecular mechanism underlying ET-1-
mediated bone formation was possibly involving the autocrine or
paracrine activation of Wnt signaling that is essential for osteoblast
proliferation, differentiation and bone development (Fig. 1). Dick-
kopf homologue 1 (DDK1) is a selective inhibitor of the Wnt
signaling pathway and its transcription rate could be suppressed by
ET-1 in calvarial organ culture73. On the other hand, recombinant
DDK1 could also inhibit the ET-1-mediated osteoblast proliferation
and new bone formation73. ET-1 interacted with DKK1 in activation
of Wnt signaling and mediating new bone formation. Microarray
analysis has uncovered several prominent expression motifs acti-
vated by ET-1 in osteoblasts71. For example, OPG (osteoprotegerin)/
Table II
Endothelin signaling in regulation of osteoblastic function
Authors Source of osteoblasts ET-1 stimulation ET receptor blockade Findings
Type A Type B Both
C. H. Kasperk et al.61 Human trabecular
bone
101e105 pg/ml 1e100 pg/ml / Increase ALP, collagen type I
production, increase bone cells
proliferation
Akiyoshi Someya et al.59 MC3T3-E1 106e1013 M / ET-1 increase the intracellular Ca2þ
concentration, DNA synthesis and cell
number, as well as the decrease in ALP
activity
H.P. von Schroeder et al.58 Calvarial cell from
fetal litters
of 21-day pregnant
Wistar rats
106e1010 M / ET-1 stimulates osteoblastic
proliferation and differentiation.
Corinne Niger et al.60 hFOB 1.19 107e108 M / Cx43 expression level could inﬂuence
the action of ET-1 on differentiation of
human Ob.
Yoshiharu Hiruma et al.62 MC3T3-E1 107e1012 M BQ123
106 mM
/ ET-1 decreases the expression of mRNA
of osteocalcin, decrease deposition of
Ca2þ, increased the production rate of
IP3
Hing-Chung Lam et al.64 HTb-96
(human osteosarcoma)
/ / Human transformed osteoblast (HTb-
96) can produce ET-1.
Mitsuhiro Shioide et al.63 ROS17/2.8
(Rat Osteosarcoma)
107e109 M / Enhancement of the abundance of
osteopontin and osteocalcinmRNAs in a
time-dependent manner.
Agui T. et al.76 Bone marrow cells
from femoral
bone of male F344/Tj
107e1011 M / ET regulates IL-6 production by bone
marrow derived stromal cells.
Sherrie L. Perkins et al.77 MC3T3-E1, primary
murine
osteoblast
0.01e100 nM BQ123
1 mM
/ ET-1 enhanced IL-6 production.
Matsuno M et al.80 MC3T3-E1 106e109 M BQ123
22 nM
BQ788
1.2 nM
/ ET-1 induces IL-6 production via PKC
H. Kawamura et al.78 MC3T3-E1 107e1010 M / PKC-dependent p42/p44 MAP kinase
activation is involved in ET-1-induced
IL-6 synthesis in osteoblast-like cells.
Haruhiko Tokuda et al.82 MC3T3-E1 3 nM, 0.1 mM / EGCG reduces ET-1 induced IL-6
synthesis in MC3T3-E1 cells and
primary cultured mouse osteoblasts
Haruhiko Tokuda et al.81 MC3T3-E1 0.1 mM / Rho-kinase is involved in regulation of
ET-1-stimulated IL-6 synthesis through
p38 MAP kinase activation
Allison M. Kitten et al.88 Fetal rat calvarial / BQ123
1 mM
BQ788
1 mM
TAK-044
100 nM
BMP-7 enhances ET-1 production but
not TGF-bata 1
Hiroko Masukawa et al.89 MC3T3-E1 0.01e100 nM / ET-1 causes activation of PKC through
both phosphoinositide and
phosphatidylcholine hydrolyzes and
lead to Pi transport
W. Windischhofer et al.90 MC3T3-E1 0.1e100 nM / ET-1einduced expression of PGHS-2
mRNA requires activation of the Rho
family of G proteins and p38 MAPK
David E. Semler et al.91 MMR-106
(Rat Osteosarcoma)
107e1011 M BQ123
105e109 M
/ / ET-1 evokes Ca2þ transient
Yoh Takuwa et al.85 MC3T3-E1 107e1011 M / ET-1 cause Ca2þ mobilization and PK C
activation
Iris Schvartz et al.92 MC3T3-E1 107 M / Activation of tyrosine kinase
phosphorylation
A. Suzuki et al.93 MC3T3-E1 0.1 mM BQ123
22 nMe2.2 mM
BQ788
1.2 nMe120 nM
Three intracellular pathways: (1)
phosphoinositide hydrolysis; (2)
phosphatidylcholine hydrolysis; and (3)
arachidonic acid release are mediated
by ETAR
A. Sin et al. / Osteoarthritis and Cartilage 23 (2015) 516e524 519RANKL (receptor activator of nuclear factor kappa-B ligand)/RANK
axis tightly controls osteoclastogenesis and maintains bone ho-
meostasis74. ET-1 stimulated the production of OPG not only in
atherosclerosis but also osteoblastic metastasis of tumor71,75. The
interplays between ET-1 and the other inﬂammatory/pro-ﬁbrotic
factors such as uroplasminogen activator, uroplasminogen acti-
vator receptor, plasminogen activator inhibitor 1, TGFb1, IL-6,
vascular endothelial growth factor and CTGF have also been re-
ported in bone marrow stromal cells and osteoblasts58,71,76e82.The intracellular molecular mechanism underling ET-1 medi-
ated bone formation may include the calcineurin/Nuclear factor of
activated T-cells (NFAT) pathway71. It was found that NFATc1 un-
derwent nuclear translocation by the stimuli of ET-1 in either the
committed and differentiated MSCs towards osteoblasts71. ET-1
could increase the intracellular calcium levels through ETAR. The
activated calcineurin by ET-1 and the calcium inﬂux induced the
dephosphorylation and nuclear translocation of NFAT family
members, which led to the formation of a transcriptional complex
Fig. 1. ET-1 signaling pathways speciﬁc to osteoblasts. ET-1 activates the Wnt pathway leading to osteoblast proliferation and differentiation; the calcineurin/NFATc1 pathway
leading to suppression of apoptosis, which encourages cell survival; as well as other genes, that together increases osteoblast proliferation and differentiation while inhibits
osteoclast activity.
A. Sin et al. / Osteoarthritis and Cartilage 23 (2015) 516e524520and transcriptional activation of NFAT-controlled genes for the
suppression of apoptosis71. ET-1 might support the survival of os-
teoblasts by activation of the calcineurin/NFAT signaling pathway.
The Rho family of G proteins, protein kinase C (PKC)80, inositol
1,4,5-trisphosphate (IP3)76 and p38 mitogen-Activated PK (MAPK)
etc.78,79, also constituted the intra-cellular ET signaling proteins.Fig. 2. The emerging role of ET-1 on the osteoarthritic joint. ET-1 induces osteoblastic pro
secretion of proinﬂammatory cytokines and neutrophil recruitment. ET-1 acts on chondr
resorption balance, leading to cartilage degradation and destruction. ET-1 also perturbs N
dysfunction and angiogenesis.First, ET-1/ETAR signaling is activated via G protein coupled re-
ceptor to phospholipase C (PLC) and phospholipase D (PLD)83,84.
PLC or PLD hydrolyzes phosphatidylinositol 4,5-bisphosphate to
form water-soluble IP3 and diacylglycerol (DAG)19, which in turn
increases intracellular calcium concentration85. DAG and elevated
intracellular calcium concentration then activates PKC19. Second,liferation and differentiation while inhibiting osteoclastic activity. ET-1 also increases
ocytes to increase MMPs production and alterations in proteoglycan production and
O production in endothelial cells and VEGF secretion, which can result in endothelial
A. Sin et al. / Osteoarthritis and Cartilage 23 (2015) 516e524 521MAPK is another downstream intracellular signaling protein of ET-
186. ET-1 was shown to activate MAPKs such as extracellular signal
regulated kinases 1 and 2 (ERK1/2), p38 MAPK and c-JNKs in car-
diomyocytes, ﬁbroblasts, glomerular mesangial cells and vascular
smooth muscle cells. ET-1 might induce VGEF expression through
activation of p38 MAPK in osteoblasts79. Last, PI3-K acts as a pro-
tein/lipid kinase and phosphorylates membrane-localized phos-
phatidylinositides to form secondary messenger phospholipids and
to activate PK B (PKB, also known as Akt) by binding to ETAR. ET-1
could induce PKB activation in cardiomyocytes, myoﬁbroblasts,
vascular endothelial cells and smooth muscle cells as well as OA
chondrocytes. PKB activation often leads to changes in the
expression of genes involved in cell survival (BAD, caspases, GSK3)
and regulation of protein synthesis (eIF4E, eIF4E-binding protein 1).
In brief, ET-1 plays a role in regulation of the physiological and
pathological osteoblastic function mainly through ETAR, involving
the activation of the extracellular (DKK1, OPG) and intracellular
signaling proteins (calcineurin/NFAT and MAPK).Perspectives
ET-1 signaling is proposed to afﬂict all types of cells in the joint,
e.g., articular chondrocytes, osteoblasts and synoviocytes in the
pathogenesis of OA (Fig. 2). First, ET-1 may exert an anabolic effect
on subchondral bone by stimulating osteoblasts and inhibiting os-
teoclasts. Uncoupling effects of ET-1 on bone remodeling might
contribute substantially to the disturbance of subchondral bone in
OA. Second, ET-1may trigger the enzymatic degradation of articular
cartilage. Third, ET-1 could recruit inﬂammatory cells into inﬂamed
joint such as neutrophils and macrophages that might account for
synovium thickening and synovitis in OA. The origins of the
elevated ET-1 could be from either local or systemic inﬂammation.
The abnormal mechanical loads might induce the repetitive micro-
damage and an inﬂammatory responsewith local production of ET-
1. The co-morbidities such as obesity, hypertension and diabetes
may also contribute to high level of ET-1 in the situation of systemic
inﬂammation. TGFb1/ET-1 signaling has been well studied in
ﬁbrotic process. It warrants further investigation whether TGFb1/
ET-1 signaling also plays a role in osteoblast dysfunction and sub-
chondral bone sclerosis in the pathogenesis of OA.Authors' contribution
Sin prepared the ﬁrst draft of this review article and Tang sup-
plemented the paragraphs and summarizing tables about the
in vitro studies of ET-1 on bone cells. Wen, Chung and Chiu pro-
posed the idea, revised the manuscript critically and approved the
ﬁnal version to be published.Competing interests
The authors declare that they have no competing interests.Acknowledgment
The authors acknowledge the support from Li Shu Fan Medical
Foundation Endowed Professorship in Orthopaedic Surgery and
Hong Kong Research Grant Council General Research Fund (HKU-
M17105314).References
1. Lories RJ, Luyten FP. The bone-cartilage unit in osteoarthritis.
Nat Rev Rheumatol 2011;7(1):43e9.2. Wang Q, Rozelle AL, Lepus CM, Scanzello CR, Song JJ,
Larsen DM, et al. Identiﬁcation of a central role for comple-
ment in osteoarthritis. Nat Med 2011;17(12):1674e9.
3. Zhen G, Wen C, Jia X, Li Y, Crane JL, Mears SC, et al. Inhibition of
TGF-beta signaling in mesenchymal stem cells of subchondral
bone attenuates osteoarthritis. Nat Med 2013;19(6):704e12.
4. Berenbaum F, Eymard F, Houard X. Osteoarthritis, inﬂamma-
tion and obesity. Curr Opin Rheumatol 2013;25(1):114e8.
5. Berenbaum F. Diabetes-induced osteoarthritis: from a new
paradigm to a new phenotype. Postgrad Med J 2012;88(1038):
240e2.
6. Wen CY, Chen Y, Tang HL, Yan CH, Lu WW, Chiu KY. Bone loss
at subchondral plate in knee osteoarthritis patients with hy-
pertension and type 2 diabetes mellitus. Osteoarthritis Carti-
lage 2013 Nov;21(11):1716e23.
7. Redlich K, Smolen JS. Inﬂammatory bone loss: pathogenesis
and therapeutic intervention. Nat Rev Drug Discov 2012;11(3):
234e50.
8. Massicotte F, Lajeunesse D, Benderdour M, Pelletier JP, Hilal G,
Duval N, et al. Can altered production of interleukin-1beta,
interleukin-6, transforming growth factor-beta and prosta-
glandin E(2) by isolated human subchondral osteoblasts
identify two subgroups of osteoarthritic patients. Osteoar-
thritis Cartilage 2002;10(6):491e500.
9. Clines GA, Mohammad KS, Grunda JM, Clines KL, Niewolna M,
McKenna CR, et al. Regulation of postnatal trabecular bone
formation by the osteoblast endothelin A receptor. J Bone Min
Res 2011;26(10):2523e36.
10. Haq A, El-Ramahi K, Al-Dalaan A, Al-Sedairy ST. Serum and
synovial ﬂuid concentrations of endothelin-1 in patients with
rheumatoid arthritis. J Med 1999;30(1e2):51e60.
11. Yoshida H, Imafuku Y, Ohhara M, Miyata M, Kasukawa R,
Ohsumi K, et al. Endothelin-1 production by human synovio-
cytes. Ann Clin Biochem 1998;35(Pt 2):290e4.
12. Nahir AM, Hoffman A, Lorber M, Keiser HR. Presence of
immunoreactive endothelin in synovial ﬂuid: analysis of 22
cases. J Rheumatol 1991;18(5):678e80.
13. Khatib AM, Lomri A, Mitrovic RD, Moldovan F. Articular chon-
drocyte aging and endothelin-1. Cytokine 2007;37(1):6e13.
14. Manacu CA, Martel-Pelletier J, Roy-Beaudry M, Pelletier JP,
Fernandes JC, Shipkolye FS, et al. Endothelin-1 in osteoarthritic
chondrocytes triggers nitric oxide production and upregulates
collagenase production. Arthritis Res Ther 2005;7(2):
R324e32.
15. Roy-Beaudry M, Martel-Pelletier J, Pelletier JP, M'Barek KN,
Christgau S, Shipkolye F, et al. Endothelin 1 promotes osteo-
arthritic cartilage degradation via matrix metalloprotease 1
and matrix metalloprotease 13 induction. Arthritis Rheum
2003;48(10):2855e64.
16. Schneider JG, Tilly N, Hierl T, Sommer U, Hamann A, Dugi K,
et al. Elevated plasma endothelin-1 levels in diabetes mellitus.
Am J Hypertens 2002;15(11):967e72.
17. Yanagisawa M, Inoue A, Ishikawa T, Kasuya Y, Kimura S,
Kumagaye S, et al. Primary structure, synthesis, and biological
activity of rat endothelin, an endothelium-derived vasocon-
strictor peptide. Proc Natl Acad Sci U S A 1988;85(18):6964e7.
18. Levin ER. Endothelins. N Engl J Med 1995;333(6):356e63.
19. Simonson MS, Dunn MJ. Cellular signaling by peptides of the
endothelin gene family. FASEB J 1990;4(12):2989e3000.
20. Vanhoutte PM. Endothelin-1. A matter of life and breath. Na-
ture 1994;368(6473):693e4.
21. Vanhoutte PM. Is endothelin involved in the pathogenesis of
hypertension? Hypertension 1993;21(6 Pt 1):747e51.
22. Leung JW, Wong WT, Koon HW, Mo FM, Tam S, Huang Y, et al.
Transgenic mice over-expressing ET-1 in the endothelial cells
A. Sin et al. / Osteoarthritis and Cartilage 23 (2015) 516e524522develop systemic hypertension with altered vascular reac-
tivity. PLoS One 2011;6(11):e26994.
23. Krum H, Viskoper RJ, Lacourciere Y, Budde M, Charlon V. The
effect of an endothelin-receptor antagonist, bosentan, on
blood pressure in patients with essential hypertension.
Bosentan Hypertension Investigators. N Engl J Med
1998;338(12):784e90.
24. Oliver FJ, de la Rubia G, Feener EP, Lee ME, Loeken MR, Shiba T,
et al. Stimulation of endothelin-1 gene expression by insulin in
endothelial cells. J Biol Chem 1991;266(34):23251e6.
25. Ottosson-Seeberger A, Lundberg JM, Alvestrand A, Ahlborg G.
Exogenous endothelin-1 causes peripheral insulin resistance
in healthy humans. Acta Physiol Scand 1997;161(2):211e20.
26. Alvarez D, Briassouli P, Clancy RM, Zavadil J, Reed JH,
Abellar RG, et al. A novel role of endothelin-1 in linking Toll-
like receptor 7-mediated inﬂammation to ﬁbrosis in congen-
ital heart block. J Biol Chem 2011;286(35):30444e54.
27. Zhang W, Wang W, Yu H, Zhang Y, Dai Y, Ning C, et al. Inter-
leukin 6 underlies angiotensin II-induced hypertension and
chronic renal damage. Hypertension 2012;59(1):136e44.
28. Mayyas F, Niebauer M, Zurick A, Barnard J, Gillinov AM,
Chung MK, et al. Association of left atrial endothelin-1 with
atrial rhythm, size, and ﬁbrosis in patients with structural heart
disease. Circ Arrhythm Electrophysiol 2010;3(4):369e79.
29. Lagares D, Garcia-Fernandez RA, Jimenez CL, Magan-
Marchal N, Busnadiego O, Lamas S, et al. Endothelin 1 con-
tributes to the effect of transforming growth factor beta1 on
wound repair and skin ﬁbrosis. Arthritis Rheum 2010;62(3):
878e89.
30. Shi-Wen X, Rodriguez-Pascual F, Lamas S, Holmes A, Howat S,
Pearson JD, et al. Constitutive ALK5-independent c-Jun N-ter-
minal kinase activation contributes to endothelin-1 over-
expression in pulmonary ﬁbrosis: evidence of an autocrine
endothelin loop operating through the endothelin A and B
receptors. Mol Cell Biol 2006;26(14):5518e27.
31. Kambas K, Chrysanthopoulou A, Kourtzelis I, Skordala M,
Mitroulis I, Rafail S, et al. Endothelin-1 signaling promotes
ﬁbrosis in vitro in a bronchopulmonary dysplasia model by
activating the extrinsic coagulation cascade. J Immunol
2011;186(11):6568e75.
32. Widyantoro B, Emoto N, Nakayama K, Anggrahini DW,
Adiarto S, Iwasa N, et al. Endothelial cell-derived endothelin-1
promotes cardiac ﬁbrosis in diabetic hearts through stimula-
tion of endothelial-to-mesenchymal transition. Circulation
2010;121(22). 2407-U88.
33. Pache M, Schwarz HA, Kaiser HJ, Wuest P, Kloti M, Dubler B,
et al. Elevated plasma endothelin-1 levels and vascular dys-
regulation in patients with rheumatoid arthritis. Med Sci
Monit 2002;8(9):CR616e9.
34. Leask A. Signaling in ﬁbrosis: targeting the TGF beta,
endothelin-1 and CCN2 axis in scleroderma. Front Biosci (Elite
Ed) 2009;1:115e22.
35. Leung JW, Chung SS, Chung SK. Endothelial endothelin-1 over-
expression using receptor tyrosine kinase tie-1 promoter leads
to more severe vascular permeability and blood brain barrier
breakdown after transient middle cerebral artery occlusion.
Brain Res 2009;1266:121e9.
36. Iwabuchi H, Kasama T, Hanaoka R, Miwa Y, Hatano Y,
Kobayashi K, et al. Downregulation of intercellular adhesion
molecule-1 expression on human synovial ﬁbroblasts by
endothelin-1. J Rheumatol 1999;26(3):522e31.
37. Schwarting A, Schlaak J, Lotz J, Pfers I, Meyer zum
Buschenfelde KH, Mayet WJ. Endothelin-1 modulates the
expression of adhesion molecules on ﬁbroblast-like synovial
cells (FLS). Scand J Rheumatol 1996;25(4):246e56.38. Conte Fde P, Barja-Fidalgo C, Verri Jr WA, Cunha FQ, Rae GA,
Penido C, et al. Endothelins modulate inﬂammatory reaction in
zymosan-induced arthritis: participation of LTB4, TNF-alpha,
and CXCL-1. J Leukoc Biol 2008;84(3):652e60.
39. Kuryliszyn-Moskal A, Klimiuk PA, Sierakowski S,
Ciolkiewicz M. A study on vascular endothelial growth factor
and endothelin-1 in patients with extra-articular involvement
of rheumatoid arthritis. Clin Rheumatol 2006;25(3):314e9.
40. Usmani SE, Appleton CT, Beier F. Transforming growth factor-
alpha induces endothelin receptor A expression in osteoar-
thritis. J Orthop Res 2012;30(9):1391e7.
41. Messai H, Khatib AM, Lebrun G, Aubin P, Florina M, Jean F, et al.
Endothelin-1 in monolayer cultures of articular chondrocytes
from young and old rats: regulation by growth factors and
cytokines. Mech Ageing Dev 2000;114(1):37e48.
42. Wen CY, Yan CH, Chung SK, Chiu KY. Development of
osteoarthritis-like changes in transgenic endothelin-1 over-
expressed mice, The Thirteen International Conference on
Endothelin Tokyo, Japan 2013.
43. Khatib AM, Lomri A, Moldovan F, Soliman H, Fiet J,
Mitrovic DR. Endothelin 1 receptors, signal transduction and
effects on DNA and proteoglycan synthesis in rat articular
chondrocytes. Cytokine 1998;10(9):669e79.
44. Khatib AM, Siegfried G, Messai H, Moldovan F, Mitrovic DR.
Mechanism of inhibition of endothelin-1-stimulated proteo-
glycan and collagen synthesis in rat articular chondrocytes.
Cytokine 2002;17(5):254e61.
45. Yuan W, Zhao MD, Yuan FL, Che W, Duan PG, Liu Y, et al. As-
sociation of endothelin-1 expression and cartilaginous end-
plate degeneration in humans. PLoS One 2013;8(4):e60062.
46. Gokin AP, Fareed MU, Pan HL, Hans G, Strichartz GR, Davar G.
Local injection of endothelin-1 produces pain-like behavior
and excitation of nociceptors in rats. J Neurosci 2001;21(14):
5358e66.
47. Griswold DE, Douglas SA, Martin LD, Davis TG, Davis L, Ao Z,
et al. Endothelin B receptor modulates inﬂammatory pain and
cutaneous inﬂammation. Mol Pharmacol 1999;56(4):807e12.
48. Kaufman GN, Zaouter C, Valteau B, Sirois P, Moldovan F.
Nociceptive tolerance is improved by bradykinin receptor B1
antagonism and joint morphology is protected by both endo-
thelin type A and bradykinin receptor B1 antagonism in a
surgical model of osteoarthritis. Arthritis Res Ther 2011;13(3).
49. Torres L, Dunlop DD, Peterfy C, Guermazi A, Prasad P,
Hayes KW, et al. The relationship between speciﬁc tissue le-
sions and pain severity in persons with knee osteoarthritis.
Osteoarthritis Cartilage 2006;14(10):1033e40.
50. Suri S, Gill SE, Massena de Camin S, Wilson D, McWilliams DF,
Walsh DA. Neurovascular invasion at the osteochondral junc-
tion and in osteophytes in osteoarthritis. Ann Rheum Dis
2007;66(11):1423e8.
51. Pecchi E, Priam S, Gosset M, Pigenet A, Sudre L, Laiguillon MC,
et al. Induction of nerve growth factor expression and release
by mechanical and inﬂammatory stimuli in chondrocytes:
possible involvement in osteoarthritis pain. Arthritis Res Ther
2014;16(1):R16.
52. Ieda M, Fukuda K, Hisaka Y, Kimura K, Kawaguchi H, Fujita J,
et al. Endothelin-1 regulates cardiac sympathetic innervation
in the rodent heart by controlling nerve growth factor
expression. J Clin Invest 2004;113(6):876e84.
53. Hunter DJ, Gerstenfeld L, Bishop G, Davis AD, Mason ZD,
Einhorn TA, et al. Bone marrow lesions from osteoarthritis
knees are characterized by sclerotic bone that is less well
mineralized. Arthritis Res Ther 2009;11(1):R11.
54. Couchourel D, Aubry I, Delalandre A, Lavigne M, Martel-
Pelletier J, Pelletier JP, et al. Altered mineralization of human
A. Sin et al. / Osteoarthritis and Cartilage 23 (2015) 516e524 523osteoarthritic osteoblasts is attributable to abnormal type I
collagen production. Arthritis Rheum 2009;60(5):1438e50.
55. Sanchez C, Deberg MA, Piccardi N, Msika P, Reginster JY,
Henrotin YE. Subchondral bone osteoblasts induce phenotypic
changes in human osteoarthritic chondrocytes. Osteoarthritis
Cartilage 2005;13(11):988e97.
56. Kurihara Y, Kurihara H, Suzuki H, Kodama T, Maemura K,
Nagai R, et al. Elevated blood pressure and craniofacial ab-
normalities in mice deﬁcient in endothelin-1. Nature
1994;368(6473):703e10.
57. Kitano Y, Kurihara H, Kurihara Y, Maemura K, Ryo Y, Yazaki Y,
et al. Gene expression of bone matrix proteins and endothelin
receptors in endothelin-1-deﬁcient mice revealed by in situ
hybridization. J Bone Min Res 1998;13(2):237e44.
58. von Schroeder HP, Veillette CJ, Payandeh J, Qureshi A,
Heersche JN. Endothelin-1 promotes osteoprogenitor prolif-
eration and differentiation in fetal rat calvarial cell cultures.
Bone 2003;33(4):673e84.
59. Someya A, Yuyama H, Fujimori A, Ukai M, Fukushima S,
Sasamata M. Effect of YM598, a selective endothelin ETA re-
ceptor antagonist, on endothelin-1-induced bone formation.
Eur J Pharmacol 2006;543(1e3):14e20.
60. Niger C, Geneau G, Fiorini C, Defamie N, Pointis G, Mesnil M,
et al. Endothelin-1 inhibits human osteoblastic cell differenti-
ation: inﬂuence of connexin-43 expression level. J Cell Bio-
chem 2008;103(1):110e22.
61. Kasperk CH, Borcsok I, Schairer HU, Schneider U, Nawroth PP,
Niethard FU, et al. Endothelin-1 is a potent regulator of human
bone cell metabolism in vitro. Calcif Tissue Int 1997;60(4):
368e74.
62. Hiruma Y, Inoue A, Shiohama A, Otsuka E, Hirose S,
Yamaguchi A, et al. Endothelins inhibit the mineralization of
osteoblastic MC3T3-E1 cells through the A-type endothelin
receptor. Am J Physiol 1998;275(4 Pt 2):R1099e105.
63. Shioide M, Noda M. Endothelin modulates osteopontin and
osteocalcin messenger ribonucleic acid expression in rat
osteoblastic osteosarcoma cells. J Cell Biochem 1993;53(2):
176e80.
64. Lam HC, Lee JK, Lai KH. Detection and characterization of
endothelin in transformed human osteoblast cell culture me-
dium. Endocrine 2000;12(1):77e80.
65. Sasaki T, Hong MH. Localization of endothelin-1 in the osteo-
clast. J Electron Microsc (Tokyo) 1993;42(3):193e6.
66. Alam AS, Gallagher A, Shankar V, Ghatei MA, Datta HK,
Huang CL, et al. Endothelin inhibits osteoclastic bone resorp-
tion by a direct effect on cell motility: implications for the
vascular control of bone resorption. Endocrinology
1992;130(6):3617e24.
67. Drevensek M, Sprogar S, Boras I, Drevensek G. Effects of
endothelin antagonist tezosentan on orthodontic tooth
movement in rats. Am J Orthod Dentofac Orthop 2006;129(4):
555e8.
68. Sprogar S, Volk J, Drevensek M, Drevensek G. The effects of
TBC3214, a selective endothelin ETA receptor antagonist, on
orthodontic tooth movement in rats. Eur J Orthod 2007;29(6):
605e8.
69. Sprogar S, Vaupotic T, Cor A, Drevensek M, Drevensek G. The
endothelin system mediates bone modeling in the late stage of
orthodontic tooth movement in rats. Bone 2008;43(4):740e7.
70. Nelson JB, Hedican SP, George DJ, Reddi AH, Piantadosi S,
Eisenberger MA, et al. Identiﬁcation of endothelin-1 in the
pathophysiology of metastatic adenocarcinoma of the pros-
tate. Nat Med 1995;1(9):944e9.
71. Van Sant C, Wang G, Anderson MG, Trask OJ, Lesniewski R,
Semizarov D. Endothelin signaling in osteoblasts: globalgenome view and implication of the calcineurin/NFAT
pathway. Mol Cancer Ther 2007;6(1):253e61.
72. Carducci MA, Jimeno A. Targeting bone metastasis in prostate
cancer with endothelin receptor antagonists. Clin Cancer Res
2006;12(20 Pt 2):6296se300s.
73. Clines GA, Mohammad KS, Bao Y, Stephens OW, Suva LJ,
Shaughnessy Jr JD, et al. Dickkopf homolog 1 mediates endo-
thelin-1-stimulated new bone formation. Mol Endocrinol
2007;21(2):486e98.
74. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS,
Luthy R, et al. Osteoprotegerin: a novel secreted protein
involved in the regulation of bone density. Cell 1997;89(2):
309e19.
75. Hakimi M, Hyhlik-Durr A, von Au A, Betz M, Demirel S,
Dihlmann S, et al. The expression of glycophorin A and
osteoprotegerin is locally increased in carotid atherosclerotic
lesions of symptomatic compared to asymptomatic patients.
Int J Mol Med 2013;32(2):331e8.
76. Agui T, Xin X, Cai Y, Sakai T, Matsumoto K. Stimulation of
interleukin-6 production by endothelin in rat bone marrow-
derived stromal cells. Blood 1994;84(8):2531e8.
77. Perkins SL, Sarraj E, Kling SJ, Kohan DE. Endothelin stimulates
osteoblastic production of IL-6 but not macrophage colony-
stimulating factor. Am J Physiol 1997;272(3 Pt 1):E461e8.
78. Kawamura H, Otsuka T, Tokuda H, Matsuno H, Niwa M,
Matsui N, et al. Involvement of p42/p44 MAP kinase in endo-
thelin-1-induced interleukin-6 synthesis in osteoblast-like
cells. Bone 1999;24(4):315e20.
79. Kozawa O, Kawamura H, Hatakeyama D, Matsuno H,
Uematsu T. Endothelin-1 induces vascular endothelial growth
factor synthesis in osteoblasts: involvement of p38 mitogen-
activated protein kinase. Cell Signal 2000;12(6):375e80.
80. Matsuno M, Kozawa O, Suzuki A, Tokuda H, Kaida T,
Matsuno H, et al. Involvement of protein kinase C activation in
endothelin-1-induced secretion of interleukin-6 in osteoblast-
like cells. Cell Signal 1998;10(2):107e11.
81. Tokuda H, Hanai Y, Matsushima-Nishiwaki R, Yamauchi J,
Doi T, Harada A, et al. Rho-kinase regulates endothelin-1-
stimulated IL-6 synthesis via p38 MAP kinase in osteoblasts.
Biochem Biophys Res Commun 2007;362(4):799e804.
82. Tokuda H, Takai S, Hanai Y, Matsushima-Nishiwaki R, Hosoi T,
Harada A, et al. (-)-Epigallocatechin gallate suppresses endo-
thelin-1-induced interleukin-6 synthesis in osteoblasts: inhi-
bition of p44/p42 MAP kinase activation. FEBS Lett
2007;581(7):1311e6.
83. Takuwa Y, Masaki T, Yamashita K. The effects of the endothelin
family peptides on cultured osteoblastic cells from rat calvariae.
Biochem Biophys Res Commun 1990;170(3):998e1005.
84. Suzuki A, Oiso Y, Kozawa O. Effect of endothelin-1 on phos-
pholipase D activity in osteoblast-like cells. Mol Cell Endo-
crinol 1994;105(2):193e6.
85. Takuwa Y, Ohue Y, Takuwa N, Yamashita K. Endothelin-1 ac-
tivates phospholipase C and mobilizes Ca2þ from extra- and
intracellular pools in osteoblastic cells. Am J Physiol
1989;257(6 Pt 1):E797e803.
86. Bouallegue A, Daou GB, Srivastava AK. Endothelin-1-induced
signaling pathways in vascular smooth muscle cells. Curr
Vasc Pharmacol 2007;5(1):45e52.
87. Miyasaka N, Hirata Y, Ando K, Sato K, Morita H, Shichiri M,
et al. Increased production of endothelin-1 in patients with
inﬂammatory arthritides. Arthritis Rheum 1992;35(4):
397e400.
88. Kitten AM, Andrews CJ. Endothelin-1 expression in long-term
cultures of fetal rat calvarial osteoblasts: regulation by BMP-7.
J Cell Physiol 2001;187(2):218e25.
A. Sin et al. / Osteoarthritis and Cartilage 23 (2015) 516e52452489. Masukawa H, Miura Y, Sato I, Oiso Y, Suzuki A. Stimulatory
effect of endothelin-1 on Na-dependent phosphate transport
and its signaling mechanism in osteoblast-like cells. J Cell
Biochem 2001;83(1):47e55.
90. Windischhofer W, Zach D, Fauler G, Raspotnig G, Kofeler H,
Leis HJ. Involvement of Rho and p38 MAPK in endothelin-1-
induced expression of PGHS-2 mRNA in osteoblast-like cells.
J Bone Min Res 2002;17(10):1774e84.
91. Semler DE, Ohlstein EH, Nambi P, Slater C, Stern PH. Endo-
thelin-1-evoked calcium transients in Umr-106 osteoblasticosteosarcoma cells are mediated through endothelin-a and
endothelin-B receptors. J Pharmacol Exp Ther 1995;272(3):
1052e8.
92. Schvartz I, Ittoop O, Davidai G, Hazum E. Endothelin rapidly
stimulates tyrosine phosphorylation in osteoblast-like cells.
Peptides 1992;13(1):159e63.
93. Suzuki A, Shinoda J, Watanabe-Tomita Y, Ozaki N, Oiso Y,
Kozawa O. ETA receptor mediates the signaling of endothelin-
1 in osteoblast-like cells. Bone 1997;21(2):143e6.
